• About
  • Subscribe
  • Advertise
  • Contact
Sunday, July 13, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Products

Zeiss builds blue light blocking tech into next-gen lens

by Staff Writer
January 18, 2022
in Lenses, Products
Reading Time: 3 mins read
A A
BluePro Lenses block a part of the blue light spectrum that could exacerbate digital eye strain symptoms.

BluePro Lenses block a part of the blue light spectrum that could exacerbate digital eye strain symptoms.

Share on FacebookShare on Twitter

Zeiss Vision Care has introduced new technology for device-dependent patients by incorporating blue light blocking properties into its lens chemical structure, helping to reduce disruptive reflections on the lens surface.

As eyewear consumers seek greater eye protection from digital devices, modern LED light exposure and during outdoor activities, the company’s new generation ZEISS BluePro Lenses are said overcome common disadvantages in many blue light blocking solutions.

Compared to the current blue light coating ZEISS DuraVision BlueProtect, the reflections of digital blue light are reduced by up to 50%.

As a result, Zeiss says the ZEISS BluePro lens design offers excellent lens clarity and can block up to 40% of the potentially harmful and irritating blue light in the wavelength between 400 and 455nm, which it says has known links to digital eye strain.

ZEISS BluePro lenses also come standard with ZEISS DuraVision Platinum UV, offering full UV protection up to 400nm.

Dr Christian Lappe, director technical communication at ZEISS, said digital screens and indoor LED lighting emit a higher proportion of blue light than traditional incandescent or halogen-type light bulbs.

“In addition, we are often exposed to this blue light for long periods of time, often until late at night at short visual distances. This combination of excessive near work and chromatic intraocular challenges linked to blue light strains the eye muscles and can contribute to visual discomfort and asthenopic symptoms associated with digital eye strain,” he said.

ZEISS BluePro Lenses block a part of the blue light spectrum that could exacerbate symptoms of digital eye strain, including tired eyes, blurred vision, sleep disturbances and dry or irritated eyes. The positive properties of blue light, ranging from about 455 to 500 nm, remain unaffected.

In general, the company stated that high-energy visible light (part of the blue light spectrum) is presumed to have an influence on sleep and alertness, mood and concentration.

It noted the relatively high levels of energy inherent in the comparatively short wavelengths of blue light have also been shown to impact metabolic processes in retinal cells, making it possible that excessive blue light exposure could lead to retinal damage.

“However, it is still part of medical research to better determine what dose and what specific light sources have a significant damage-causing potential,” Zeiss said.

“While caution is advised when exposing the eye to high intensity daylight from the sun, there is a relief for eyes exposed to digital devices, displays, monitors or normal illumination. In fact, there is currently no evidence from patient studies that these devices pose a health risk to the retina. Nevertheless, patient complaints of decreased visual comfort, asthenopic symptoms such as blurred vision, burning, painful or tired eyes, and eyestrain are common and familiar topics to eyecare professionals.”

More reading

Dr Rene Hessling replaces Joe Redner as Zeiss ANZ managing director

Gail Giordani appointed to head Zeiss Vision Care ANZ

Zeiss SmartLife lens for connected lifestyles

Tags: blockingblue lightBlueProdigital eye strainlensesZeissZeiss Vision Care

Related Posts

Myopia is surging around the world, and particularly among children. New studies show that HOYA's DIMS technology can have a lasting impact in treatment. Image: HOYA.

New evidence backs HOYA’s DIMS technology to combat myopia

by Staff Writer
July 11, 2025

HOYA Vision Care has announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple...

EYLEA 8 mg is indicated in adults for neovascular age-related macular degeneration and diabetic macular oedema. Image: dragonstock/stock.adobe.com.

EC approves use of Eylea 8mg for extended treatment intervals

by Staff Writer
July 10, 2025

The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8mg (aflibercept 8mg, 114.3mg/ml...

Design Eyewear Group CEO Lars Flyvholm. Image: Design Eyewear Group.

VMD Eyewear named to distribute Jaguar eyewear in Australia

by Staff Writer
July 8, 2025

Design Eyewear Group (DEG) has appointed VMD Eyewear as the exclusive distributor of Jaguar Eyewear in Australia. Just last month,...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited